Haemonetics Reports Q2 Fiscal Results with Earnings and Revenue Beats
Haemonetics (NYSE: HAE) reported second-quarter fiscal results that exceeded analyst expectations on both the top and bottom lines. The company posted a Non-GAAP earnings per share (EPS) of $1.35, surpassing estimates by $0.06, while revenue reached $357.8 million, representing a 9.4% increase year-over-year and beating projections by $12.65 million. The company's liquidity position also showed improvement, with cash on hand reaching $260.7 million as of September 26, 2026. This reflects an increase of $15.3 million since the end of fiscal 2026, driven primarily by cash flow generation.
Tickers: $HAE
Topics: cash flow earnings beat revenue growth